FDA Approves Kyprolis as Second-Line Treatment for Multiple Myeloma

Share this content:
The FDA has granted accelerated approval for Kyprolis (carfilzomib) as second-line treatment for patients with multiple myeloma.
The FDA has granted accelerated approval for Kyprolis (carfilzomib) as second-line treatment for patients with multiple myeloma.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone as second-line treatment for patients with multiple myeloma.

The approval is based on results from a phase 3 trial that evaluated carfilzomib in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in 792 patients with relapsed or refractory multiple myeloma after one to three lines of prior therapy. Patients were treated for a maximum of 18 cycles.

Results of that study (ASPIRE) showed a statistically significant improvement in progression-free survival with the three-drug combination compared with the two-drug combination.

In regard to safety, adverse events related to carfilzomib were similar to those described in the current prescribing information. Researchers found that cardiovascular events, venous thromboembolic events, and thrombocytopenia were more common in the carfilzomib group.

RELATED: Similar Outcomes of Three Different Treatment Regimens Reported in Multiple Myeloma

The approval also includes a labeling change for Warnings and Precautions to alert health care professionals of the risk for venous thromboembolic events, cardiotoxicities, acute renal failure, pulmonary toxicities, and hypertension.

The FDA initially approved carfilzomib in 2012 for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Reference

  1. Carfilzomib/Kyprolis. U.S. Food and Drug Administration: Approved Drugs. July 24, 2015. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455873.htm. Accessed July 24, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs